Generic Semaglutide in India (2026): Brands, Prices, and What You Need to Know

TL;DR: Novo Nordisk's semaglutide patent expired in India on March 20, 2026. Within days, over 40 pharmaceutical companies launched more than 50 generic brands. Prices dropped 70% to 90% compared to branded Ozempic and Wegovy: generic multi-dose vials start at roughly ₹1,290 per month, and pre-filled pens range from ₹3,000 to ₹4,500 per month (compared to ₹8,800 to ₹16,400 for originator brands). Semaglutide remains prescription-only in India for both diabetes and weight management. The CDSCO has approved it for chronic weight management in adults with a BMI of 30 or above (or 27 with comorbidities), and has simultaneously cracked down on unsupervised sales and influencer-driven promotion.

Novo Nordisk's Indian patent on semaglutide expired on March 20, 2026. The response from India's pharmaceutical industry was immediate: Sun Pharma, Zydus Lifesciences, Dr. Reddy's, and Glenmark all launched generic versions on Day 1. More followed within the week.

For the millions of Indians with type 2 diabetes and the growing number seeking medically supervised weight management, this patent expiry changes the math entirely. A drug that previously cost ₹8,800 to ₹16,400 per month is now available starting at ₹1,290.

Here's everything you need to know about the generic semaglutide landscape in India right now.

Which Generic Brands Are Available?

As of late March 2026, at least six major manufacturers have launched branded generics, with dozens more expected throughout the year. The market is moving fast, so this list will grow.

Sun Pharmaceutical

Sun Pharma launched two distinct brands:

• Noveltreat (for weight management): available as a pre-filled pen, with weekly therapy costs of ₹900 to ₹2,000 depending on the dose
• Sematrinity (for type 2 diabetes): weekly therapy costs of ₹750 to ₹1,300

Sun Pharma was among the first to receive CDSCO Subject Expert Committee approval specifically for the weight management indication.

Dr. Reddy's Laboratories

• Obeda: priced at approximately ₹4,200 per month, available in 2mg and 4mg strengths as pre-filled pens. Currently marketed for type 2 diabetes.

Zydus Lifesciences

Zydus launched three brands:

• Semaglyn, Mashema, and Alterme: averaging ₹2,200 per month

Zydus also introduced a reusable multi-dose pen device (15mg/3ml cartridge), which brings per-dose costs down further by reducing packaging and device waste. This is a meaningful innovation; most originator semaglutide products use single-use disposable pens.

Zydus also partnered with Lupin for co-marketing, with Lupin selling the same formulations under the brand names Semanext and Livarise.

Glenmark Pharmaceuticals

• Glipiq: launched for diabetes management. Available as both multi-dose vials (₹325 to ₹440 per week, roughly ₹1,300 to ₹1,760 per month) and pre-filled pens in 2mg, 4mg, and 8mg strengths.

Natco Pharma

• Launched multi-dose vials at ₹1,290 per month for 2mg and 4mg doses, making it the cheapest option at launch. Pre-filled pens are expected at ₹4,000 to ₹4,500 per month, with an April 2026 launch date.

Other Manufacturers

Eris Lifesciences launched vials in a similar price range to Natco. Alkem Laboratories received CDSCO SEC approval specifically for the obesity/weight management indication. Mankind Pharma and Macleods Pharmaceuticals are also entering the market, with Macleods conducting bioequivalence studies for pre-filled pen formulations across five dose strengths (0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg).

Industry estimates project over 50 branded generic semaglutide products will be available in India by the end of 2026.

What Do They Cost Compared to the Originals?

The price difference is dramatic.

Branded originator pricing (Novo Nordisk):

• Ozempic (for diabetes): ₹8,800 to ₹11,175 per month
• Wegovy (for weight management): up to ₹16,400 per month

Generic pricing range:

| Format | Monthly Cost | Savings vs Ozempic | |--------|-------------|-------------------| | Multi-dose vials (Natco, Eris, Glenmark) | ₹1,290 to ₹1,760 | 80% to 85% cheaper | | Pre-filled pens (Dr. Reddy's, Sun Pharma) | ₹3,000 to ₹4,500 | 50% to 65% cheaper | | Reusable multi-dose pen (Zydus) | ~₹2,200 | ~75% cheaper |

For context, at the lowest generic price point of ₹1,290 per month, the annual cost of semaglutide therapy comes to roughly ₹15,480 (approximately $185 USD). That's a fraction of the $11,600+ annual cost of branded Ozempic in the United States, which helps explain why India's generic market is attracting global attention. For a full breakdown of US pricing, see how much Ozempic costs per month.

Vials vs Pre-Filled Pens: Which Format to Choose

The two main formats serve different needs:

Multi-dose vials are the most affordable option (₹1,290 to ₹1,760/month). They require you to draw the correct dose using a syringe, which means some comfort with self-injection technique. Your doctor or pharmacist can demonstrate this. Vials also require proper storage and handling, since the vial is used for multiple doses over several weeks.

Pre-filled pens are more convenient. The dose is dialed in, the needle is pre-attached or easily attached, and there's less room for dosing error. They cost roughly 2x to 3x more than vials (₹3,000 to ₹4,500/month), which is still a steep discount from the originator pen price.

Reusable multi-dose pens (the Zydus device) split the difference: pen convenience with cartridge-based refills that bring costs closer to vial territory.

Who Can Get a Prescription?

Semaglutide is a prescription-only medication in India. You cannot legally purchase it over the counter, and the CDSCO has been actively cracking down on unauthorized retail and online sales.

Approved Indications

The CDSCO has approved generic semaglutide for two categories:

Type 2 diabetes: as an adjunct to diet and exercise to improve blood sugar control. This is the more established indication, and most generic brands launched with this approval.

Chronic weight management: as an adjunct to a reduced-calorie diet and increased physical activity for adults with:

• A BMI of 30 kg/m² or greater (obesity), OR
• A BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia

Sun Pharma and Alkem were among the first generic manufacturers to receive specific CDSCO SEC approval for the weight management indication. Other manufacturers are expected to follow with their own weight management approvals throughout 2026.

Where to Get a Prescription

You'll need to see a registered medical practitioner. In practice, this means:

• Endocrinologists are the most common prescribers for both diabetes and weight management
• Diabetologists regularly prescribe for type 2 diabetes patients
• General physicians can prescribe, though some may refer you to a specialist for the weight management indication
• Bariatric medicine specialists for weight management cases

Once you have a prescription, generic semaglutide is available through:

• Retail pharmacies (Apollo, MedPlus, and local chemists)
• Online pharmacies such as 1mg, PharmEasy, and Netmeds (prescription upload required)
• Hospital pharmacies at the prescribing institution

Online pharmacy platforms already list several generic brands. For example, Sun Pharma's Noveltreat pre-filled pen is available on 1mg.com, and Wegovy is listed on PharmEasy. Both platforms require a valid prescription before dispensing.

Safety, Quality, and What to Watch For

The flood of 50+ generic brands raises legitimate questions about quality and safety. Here's how to think about it.

CDSCO Oversight Is Tightening

The CDSCO has responded to the generic wave by intensifying regulatory surveillance. In March 2026 alone, the regulator conducted inspections across 49 entities including pharmacies, wholesalers, and clinics. The focus: detecting unauthorized sales, misleading promotional practices, and off-label dispensing without prescriptions.

Penalties for non-compliance include license cancellation and criminal prosecution. This is a meaningful shift in enforcement intensity.

Bioequivalence Requirements

Generic manufacturers must demonstrate bioequivalence to the originator product through formal studies. The CDSCO Subject Expert Committee reviews animal toxicity data and bioequivalence reports before granting marketing approval. Macleods Pharmaceuticals, for example, was required to complete BE studies across five dose strengths before receiving approval for its pre-filled pen formulations.

This means approved generics should deliver the same clinical effect as branded Ozempic or Wegovy at equivalent doses. The active ingredient is the same molecule: semaglutide.

Promotional Restrictions

The CDSCO has imposed strict guidelines on how semaglutide can be promoted in India. Prohibited activities include:

• Disease awareness campaigns used as surrogate advertising
• Influencer engagement or endorsements
• Direct-to-consumer promotional activities

These restrictions exist because of concerns about semaglutide being marketed for cosmetic weight loss in people who don't meet the clinical criteria.

Practical Safety Advice

Some sensible precautions when starting generic semaglutide:

• Only use a product prescribed by your doctor. Avoid purchasing from unauthorized sellers or social media ads, even if the price looks attractive.
• Stick with established manufacturers. Sun Pharma, Dr. Reddy's, Zydus, Glenmark, and Natco are large-scale pharmaceutical companies with extensive manufacturing track records.
• Follow the dose titration schedule. Semaglutide is started at a low dose (typically 0.25mg weekly) and increased gradually over 16 to 20 weeks. Skipping this ramp-up to "get results faster" is a common cause of severe nausea and GI side effects.
• Report adverse events. India's Pharmacovigilance Programme (PvPI) accepts adverse drug reaction reports through your prescribing doctor or directly through the CDSCO website.

For a broader view of semaglutide's safety profile, including organ-by-organ considerations, see what organ Ozempic is hard on.

How Novo Nordisk Is Responding

Novo Nordisk anticipated generic competition but was overwhelmed by the scale. The company reportedly expected 5 to 7 competitors; it got 40+ within the first week.

Novo's strategy has three prongs:

Pre-emptive price cuts. In December 2025, Novo Nordisk cut Wegovy's price in India by 37%. This moved their market share from 13% to 21% by February 2026, but it remains a premium product relative to generics.

Clinical positioning. Novo is emphasizing the depth of clinical trial data behind its branded products (the STEP and SUSTAIN trial programs), arguing that decades of safety and efficacy data give physicians more confidence than newly approved generics.

Strategic partnerships. Novo has partnered with Abbott and Emcure to expand distribution and access in India, particularly in Tier 2 and Tier 3 cities where its direct sales presence is thinner.

Whether these moves will hold up against 90% price discounts remains to be seen. In most pharmaceutical markets, price wins in the long run once physicians are comfortable with generic bioequivalence.

What This Means for the Broader Market

India's semaglutide market is estimated to reach $1 billion over the next two years. The GLP-1 drug category in India was valued at roughly ₹1,446 crore in 2025, with semaglutide-based products accounting for ₹445 crore of that. Industry projections suggest the market will expand fivefold within five years as prices drop and awareness grows.

Eli Lilly's Mounjaro (tirzepatide) is also in the Indian market and became India's top-selling GLP-1 drug by value within months of its launch. For a comparison of how semaglutide and tirzepatide differ, see the four main GLP-1 drugs explained.

India is also one of the first major markets where semaglutide's patent has expired. Canada's patent expired in January 2026, and patents in Brazil, Turkey, and China are expiring throughout the year. India's experience will likely preview what happens in these markets as generic competition arrives.

The Bottom Line

Generic semaglutide is here in India, it's dramatically cheaper, and it's available from reputable manufacturers. Monthly costs range from ₹1,290 (vials) to ₹4,500 (pre-filled pens), compared to ₹8,800 to ₹16,400 for Novo Nordisk's branded versions.

The key caveats: you need a prescription from a registered medical practitioner, you should use products from established manufacturers, and you should follow the standard dose titration schedule under medical supervision. The CDSCO is actively enforcing these requirements.

For anyone who has been priced out of semaglutide therapy, March 2026 marks a genuine turning point. The drug that transformed obesity treatment globally is now accessible to a vastly larger population.

If you're weighing semaglutide alongside other approaches, see the best weight loss peptides ranked by evidence. And if you're interested in building sustainable habits that support long-term results (with or without medication), understanding why diets fail at the psychological level is a useful starting point.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication, including semaglutide. Dosing, eligibility, and pricing may vary based on your individual health status and the specific generic product prescribed.

Ready to stop fighting your cravings and start reprogramming your mind for lasting success? The Hypna AI 21-day self-hypnosis program is designed to help you rewire subconscious patterns and build a healthier relationship with food from the inside out.